(Updated - March 7, 2024 11:20 AM EST)
Investing.com -- Main U.S. indexes gained Thursday, as investors awaited the second day of testimony of Fed chief Jerome Powell’s two-day testimony before Congress.
Here are some of the biggest U.S. stock movers today:
OneSpan (NASDAQ:OSPN) stock rose 25% after the cybersecurity firm announced consensus-beating quarterly earnings.
Victoria's Secret (VSCO) stock slumped 31% after the lingerie retailer unveiled soft sales guidance fueled by waning apparel demand.
New York Community Bancorp (NYSE:NYCB) stock rose 10% after the regional lender disclosed on Thursday it held deposits of $77.2 billion, down roughly 7% from the $83 billion it had on Feb. 5. It had announced that it had secured $1 billion from a group of investors.
Novo Nordisk (NYSE:NVO) stock rose 8.4% after the Danish pharmaceutical giant unveiled data for its experimental obesity drug that suggested it was more effective than its blockbuster Wegovy therapy. Rivals Lilly (LLY) and Viking Therapeutics (NASDAQ:VKTX) declined.
Rivian (NASDAQ:RIVN) stock rose 1.9% after analysts launched coverage of the EV manufacturer with a ‘buy’ rating, saying it is currently on a capital spending trajectory, which if managed successfully, could address gaps in the company's business model.
Nordstrom (NYSE:JWN) stock fell 2% after analysts downgraded their stance on the department store chain to ‘hold’ from ‘buy’, saying full-price sales "continue to underwhelm".
Big Lots (NYSE:BIG) stock fell 4% after the discount home essentials retailer reported a wider-than-expected fiscal fourth-quarter loss but provided an upbeat outlook for gross margin.
Burlington Stores (NYSE:BURL) stock rose 8% after the department store chain posted fourth-quarter income that topped average analyst estimates, even though it flagged some caution around the short-term operating environment.
Kroger (NYSE:KR) climbed 7% after the grocery chain reported strong fourth quarter results and issued a strong forecast.
Edwards Lifesciences (NYSE:EW) climbed 5.3% after analysts at BofA Securities raised their rating on the stock to ‘buy’ from ‘neutral’, citing potential for EPS growth.
Additional reporting by Louis Juricic